Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in The Lancet Neurology
Satralizumab monotherapy significantly reduced risk of relapse in patients with NMOSD, following a previous positive…